Ralph M. Steinman, professor of immunology at The Rockefeller University in New York and one of the great immunologists of our time, died on September 30 after a long fight with pancreatic cancer, just three days before the announcement that he had been awarded the Nobel Prize in Physiology or Medicine for the discovery of the dendritic cell. Steinman is universally recognized for having given birth to the vibrant field of dendritic cell biology and for having nurtured it through many years of skepticism and dispute to its current position as a central paradigm of modern immunology.
Born in a family of Jewish immigrants from Eastern Europe in Sherbrooke, Quebec, Ralph Steinman received his undergraduate degree from McGill University in 1963 and his medical degree from Harvard Medical School in 1968. He completed internship and residency training at the Massachusetts General Hospital in Boston before joining, in 1970, the laboratory of Zanvil Cohn and James Hirsch at The Rockefeller University, where he spent his entire scientific career.
The work of Ralph Steinman is a remarkable example of research focused on the understanding of the cellular basis of the immune response. In the early 1970s, it was known that an accessory cell was required for induction of adaptive immunity, but the nature of this cell was the subject of intense debate. Most researchers in the field thought that it was a macrophage, given that the cell was known to be of hematopoietic origin, present in spleen, and adherent to glass and was known to express MHC class II molecules. Because his studies with Cohn did not support a role for macrophages, Steinman set out to dissect the cellular components of the lymphoid tissues, where it was known that adaptive immunity develops after infection or vaccination. Careful microscopic analysis allowed Steinman to recognize in these tissues a new cell type with distinctive morphology that led him to denote it as ''dendritic cell.'' In a seminal paper published in the Journal of Experimental Medicine in 1973, Steinman showed that these cells were clearly different than the macrophages, according to a variety of criteria: they were motile, constantly extending and retracting many fine cell processes; had low endocytic and proteolytic activity; and expressed MHC class II molecules. Steinman developed methods to enrich or deplete mouse dendritic cells from spleen and lymph nodes that were instrumental for performing functional experiments.
In 1978, Steinman and Witmer showed that dendritic cells were the most potent cells capable of eliciting the mixed lymphocyte reaction (an in vitro correlate of a primary T cell response), being at least 100-fold more potent than unfractionated splenic cells. Steinman was the first to show a differential requirement for activation of naive versus primed T cells and to realize the implications of this finding, which was not appreciated by his contemporaries. In the 1978 paper, Steinman hypothesized that naive T lymphocytes ''may have to recognize something that exists in or on dendritic cells in addition to the MHC antigens,'' a prediction that remarkably anticipated the discovery of T cell costimulation. Steinman and coworkers were also able to discriminate the requirements for naive T cell activation from the requirements for delivery of T cell help to B cells. These studies established the central role of the dendritic cell in all of the adaptive immune responses, whether mediated by CD4 or CD8 T cells or through interaction of CD4 T cells with B cells.
In A few years after Steinman's discovery of dendritic cell maturation, Charles Janeway Jr. proposed, in a visionary article published in 1989, that the initiation of the adaptive immune response would be controlled by innate receptors specific for pathogen-associated molecular patterns, a proposal that was followed by the discovery by Jules Hoffmann and Bruce Beutler of the role of Toll-like receptors (TLRs) in pathogen recognition and in triggering innate immunity. TLRs, as well as other innate receptors, are expressed in many cell types, but it is their expression in dendritic cells and their capacity to elicit dendritic cell maturation and cytokine production that bridge innate and adaptive immunity.
In the early 1990s, the dendritic cell field became experimentally more approachable due to the development of culture methods, including those pioneered by Steinman together with Kayo Inaba, to obtain large numbers of dendritic cells starting from bone marrow precursors or from peripheral blood monocytes. The field attracted a number of researchers that became interested in understanding the cell biology of dendritic cell maturation and in identifying the stimuli and receptors that trigger the maturation process. Throughout the 1990s numerous studies dissected the mechanisms of antigen uptake, processing, and presentation; identified microbial products and inflammatory cytokines as maturation-inducing stimuli; and shed light on the regulated expression of costimulatory molecules and polarizing cytokines in maturing dendritic cells. Other studies revealed the heterogeneity and plasticity of dendritic cell populations and identified subsets specialized in priming CD4 versus CD8 T cells. Thus, after more than 20 years from the discovery, in which dendritic cell research was nearly confined in the Steinman laboratory, the field exploded into the hottest area of immunological research, with Steinman remaining the leading and guiding figure.
In line with his medical education, Steinman pioneered studies on the interaction of dendritic cells with human pathogens and showed a profound interest for the clinical application of dendritic cells as vaccines to enhance the immune responses against infectious agents and cancer or to suppress them to reduce or prevent autoimmune diseases. Steinman realized the limitations of a therapeutic approach based on in vitro-cultured dendritic cells and, together with his former student Michel Nussenzweig, designed a strategy to target dendritic cells in vivo. This approach led to the unexpected finding that antigens targeted in vivo to immature dendritic cells induce T cell tolerance, which is turned into a potent immune response if the dendritic cells also receive a maturation stimulus. These studies not only indicated a new pathway toward more effective vaccines, but also demonstrated the central role of dendritic cells in peripheral T cell tolerance, a finding that has important implications for understanding autoimmunity.
Steinman's discovery of dendritic cells as initiators and regulators of immunity represent one of the most significant advances in immunology, the importance of which continues to grow even today. His seminal contributions have been recognized by many awards, including the prestigious Gairdner and Lasker Awards in 2003 and 2007 and the Nobel Prize in 2011. Throughout his entire career, Steinman showed a total dedication to science, being an inspiring mentor for young scientists and a wonderful and generous colleague. He was also a passionate advocate for the integration of basic knowledge on dendritic cell biology into the development of new vaccines and treatments. These words best capture his contagious enthusiasm and commitment: ''Vaccine science, while exciting and important, is also really demanding. So let's help each other and share interests, findings, resources, concerns that are pertinent to this 'field of the future,' in which vaccines will be comprised of defined antigens and adjuvants, appropriate to the many medical conditions that involve the immune system.'' Antonio Lanzavecchia 1, * and Federica Sallusto 1, *
